{
  "source": "PA-Med-Nec-Lithobid.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2233-5\nProgram Prior Authorization/Medical Necessity\nMedication/Therapeutic Class Lithobid® (brand only)\nP&T Approval Date 3/2021, 3/2022, 3/2023, 11/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nThis program requires a member to try an AB-rated generic lithium prior to receiving\ncoverage for brand Lithobid.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Lithobid (brand only) will be approved based on one of the following criteria:\na. Both of the following:\n(1) History of greater than or equal to 4 week trial of generic lithium (document\ndate of trial)\n-AND-\n(2) Documented history of an inadequate response to generic lithium (document\ninadequate response)\n-OR-\nb. History of an intolerance to generic lithium which was unable to be resolved with\nattempts to minimize the adverse effects where appropriate (e.g. change timing of\ndosing, divide daily dose out for more frequent but smaller doses, lowering dose)\n-OR-\nc. Currently established on Lithobid and stable.\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Lithobid (brand only) will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nReauthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Lithobid [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc; October 2022.\n2. Gitlin, M. Lithium side effe",
    "and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Lithobid [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc; October 2022.\n2. Gitlin, M. Lithium side effects and toxicity: prevalence and management strategies. Int J\nBipolar Disord. 2016;4(1):27. Epub 2016 Dec 17.\nProgram Prior Authorization/Medical Necessity – Lithobid (brand only)\nChange Control\nDate Change\n3/2021 New program.\n3/2022 Annual review. No changes.\n3/2023 Annual review. Updated references.\n11/2023 No changes.\n7/2024 Removed therapeutic levels requirement for generic trial and stability\nduration.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}